US pharmaceutical company Eli Lilly has launched Mounjaro, a diabetes and weight-loss drug, in India. Priced at Rs 3,500 for a 2.5 mg vial, the ‘game-changing’ medication has debuted in the Indian ...

Milestone Pharmaceuticals said on Friday the U.S. health regulator had declined to approve its nasal spray to treat a type of ...

PTC Therapeutics said on Friday the European Commission will remove its inherited progressive muscle-wasting disorder from the region after an advisory panel reaffirmed a negative opinion of the drug ...

The 'big three' insulin producers Novo Nordisk, Eli Lilly, and Sanofi are being sued by the state of California for allegedly working together to set artificially inflated prices for their products.

Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...

since Novo and fellow obesity and diabetes drugmaker Eli Lilly declared their drugs were in shortage in 2022. In making his ruling, Pittman wrote that "good cause exists for Novo Nordisk's ...

Copycat versions of Eli Lilly's diabetes drug Mounjaro and obesity drug Zepbound were supposed to go away this week. They're ...

Novo Nordisk may need to sue (and win) to remove these personalized ... GLP-1 agonists has attracted competition. Novo Nordisk, Eli Lilly, and other companies, including Pfizer, are developing ...

The regulator also fired a shot across the bows of insulin manufacturers like Eli Lilly, Novo Nordisk, and Sanofi, saying that the PBMs are "not the only potentially culpable actors" for driving ...

For the bright-eyed preppies of Mackay, Isaac and the Whitsundays, it’s the beginning of a lifelong journey of learning filled with new friends and fun discoveries.